A comparison of the benefits of mitoxantrone and other recent therapeutic approaches in multiple sclerosis

Bibliography

• GOODING DS, FROHMAN EM, GARMANY GP Jr et al: Disease modifying therapies in multiple sclerosis. Report of Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology (2002) 58:169–178.
   Google Scholar
• GOODIN DS, ARNASON BG, COYLE PK, FROHMAN EM, PATY DW: The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology (2003) 61:1332–1338.
   PubMed Web of Science ®Google Scholar
• LUBLIN FD, REINGOLD SC for the National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis: Defining the clinical course of multiple sclerosis: results of an international survey. Neurology (1996) 46:907–911.
   PubMed Web of Science ®Google Scholar
• WEINSHENKER BG, BASS B, RICE GPA et al.: The natural history of multiple sclerosis: a geographically-based study. I. Clinical course and disability. Brant (1989) 112\(Part 1):133–146.
   Google Scholar
• GONSETTE RE, LISSOIR F, THEYS P, KETELAER P, DROISSART C, DEMONTY L: The natural history of MS in Belgium : a MS clinic based study. In:Multiple Sclerosis in Europe. An epidemiological update. Firnhaber W, Lauer K (Ed.), Leuchtturm-Verlag/LTV Press, Alsbach, Germany (1994):122–129.
   Google Scholar
• KURTZKE JF: Rating neurologic impairment in multiple sclerosis: anexpanded disability status scale (EDSS). Neurology (1983) 33:1444–1452.
   PubMed Web of Science ®Google Scholar
• HAWKINS SA, MCDONNELL GV: Benign multiple sclerosis? Clinical course, long term follow up, and assessment of prognostic factors. J. Neurol Neurosurg. Psychiat. (1999) 67:148–152.
   PubMed Web of Science ®Google Scholar
• WILLENBORG DO, PROWSE SJ: Immunoglobulin-deficient rats fail to develop experimental allergic encephalomyelitis.Neuroimmunol (1983) 5:99–109.
   Google Scholar
• MYERS KJ, SPRENT J,DOUGHERTY JP, RON Y: Synergy between encephalitogenic T cells and myelin basic protein-specific antibodies in the induction of experimental autoimmune encephalomyelitis.Neuroimmunol (1992) 41:1–8.
   PubMed Web of Science ®Google Scholar
• BOYLAN MT, CROCKARD AD, MCDONNELL GV, ARMSTRONG MA, HAWKINS SA: CD80 (B7-1) and CD86(B7-2) expression in multiple sclerosis patients: clinical subtype specific variation in peripheral monocytes and B cells and lack of modulation by high dose methylprednisolone.Neurol Sci. (1999) 167:79–89.
   Google Scholar
• LIPSKY PE, ATTREP JF, GRAMMER AC, MCILRAITH MJ, NISHIOKA Y: Analysis of CD40-CD40 ligand interactions in the regulation of human B cell function. Ann. NY Acad. Sci. (1997) 815:372–383.
   PubMed Web of Science ®Google Scholar
• LITZENBURGER T, FASSLER R, BAUER J et al.: B lymphocytes producing demyelinating autoantibodies development and function in gene-targeted transgenic mice. J. Exp. Med. (1998) 188:169–180.
   PubMedGoogle Scholar
• JAMES JA, HARLEY JB: B-cell epitope spreading in autoimmunity.Immunol Rev (1998) 164:185–200.
   PubMedGoogle Scholar
• MAMULA MJ: Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev (1998) 164:231–239.
   PubMedGoogle Scholar
• ROBINSON WH, FONTOURA P, LEE BJ et al.: Protein microarrays guide tolerizing DNA vaccine treatment of autoimmune encephalomyelitis. Nat. Biotechnol (2003) 21:1033–1039.
   PubMed Web of Science ®Google Scholar
• HUITINGA I, VAN ROOIJEN N, DE GROOT CJ, UITDEHAAG BM, DIJKSTRA CD: Suppression of experimental allergic encephalomyelitis in Lewis rats after elimination of macrophages. J. Exp. Med. (1990) 172:1025–1033.
   PubMed Web of Science ®Google Scholar
• TRAN EH, HOEKSTRA K,VAN ROOIJEN N, DIJKSTRA CD, OWENS T: Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice.Immunol (1998) 161:3767–3775.
   Google Scholar
• REDER AT, GENC K, BYSKOSH PV, PORRINI AM: Monocyte activation in multiple sclerosis. Malt. Scler: (1998) 4:162–168.
   PubMedGoogle Scholar
• TAN J, TOWN T, PARIS D et al: Activation of microglial cells by the CD40 pathway: relevance to multiple sclerosis. Neuroimmunol (1999) 97:77–85.
   Google Scholar
• BENVENISTE EN: Role of macrophages/microglia in multiple sclerosis and experimental allergic encephalomyelitis. Ma Med. (1997) 75:165–173.
   PubMedGoogle Scholar
• SMITH KJ, KAPOOR R, FELTS PA: Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol (1999) 9:69–92.
   PubMed Web of Science ®Google Scholar
• SAMOILOVA EB, HORTON JL, ZHANG H, CHEN Y: CD4OL blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation. Ma Med. (1997) 75:603–608.
   PubMedGoogle Scholar
• BROCK W, SOMMERMEIER N, BERGMANN M et al: Macrophages in multiple sclerosis. Immunobiology (1996) 195:588–600.
   PubMedGoogle Scholar
• SRIRAM S, RODRIGUEZ M: Indictment of the microglia as the villain in multiple sclerosis. Neurology (1997) 48:464–470.
   PubMed Web of Science ®Google Scholar
• GENAIN P, CANNELLA B,HAUSER SL, RAINE CS: Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat. Med. (1999) 5:170–175.
   PubMed Web of Science ®Google Scholar
• CONFAVREUX C, VUKUSIC S, MOREAU T: Relapses and progression of disability in multiple sclerosis. N Engl. J. Med. (2000) 343:1430–1438.
   PubMed Web of Science ®Google Scholar
• ••Relapses do not significantly influencethe progression of irreversible disability in SP MS.
   Google Scholar
• COLES A, COX A, LE PAGE E et al.:The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy in relapsing-remitting and secondary progressive disease. Malt. Scler. (2003) 9\(Suppl. 1):517.
   Google Scholar
• •Profound T-cell depletion early in the course of MS prevents axonal degeneration and delays the onset of progression.
   Google Scholar
• HENEGHAN C, BADENOCH D: Evidence-based Medicine Toolkit. Br. Med. J. Editors, London, UK (2002):65.
   Google Scholar
• THE IFNB MULTIPLE SCLEROSIS STUDY GROUP: Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double- blind, placebo-controlled trial. Neurology (1993) 43:655–661.
   Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a Phase III multicenter, double-blind, placebo-controlled trial. Neurology (1995) 45:1268–1276.
   PubMed Web of Science ®Google Scholar
• JACOBS LD, COOKFAIR DL, RUDICK RA, HERNDON RM, RICHERT JR: Intramuscular interferon beta-1 alpha for disease progression inrelapsing multiple sclerosis.Ann. Neurol (1996) 39:285–295.
   PubMed Web of Science ®Google Scholar
• PRISMS (PREVENTION OF RELAPSES AND DISABILITY BY INTERFERON BETA-1A SUBCUTANEOUSLY IN MULTIPLE SCLEROSIS) STUDY GROUP: Randomised double-blind placebo-controlled study of interferon beta-la in relapsing/remitting multiple sclerosis. Lancet (1998) 352:1498–1504.
   PubMed Web of Science ®Google Scholar
• GALETTA SL, MARKOWITZ C, LEE AG: Immunomodulatory agents for the treatment of relapsing multiple sclerosis: a systematic review. Arch. Intern. Med. (2002) 162:2161–2169.
   PubMed Web of Science ®Google Scholar
• ••Systematic review of the efficacy and safetyof immunomodulatory agents for the treatment of RR MS.
   Google Scholar
• FILIPPINI G, INCORVAIA B: Is interferon effective and safe for relapsing-remitting multiple sclerosis? Neuroepidemiology (2002) 21:310.
   Google Scholar
• O'CONNOR P, on behalf of the CANADIAN MULTIPLE SCLEROSIS WORKING GROUP: Key issues in the diagnosis and treatment of multiple sclerosis. An overview. Neurology (2002) 59 (sup3):S1–S33.
   Google Scholar
• ••An extensive overview of recently approvedtreatment option for MS.
   Google Scholar
• COMI G, FILIPPI M, WOLINSKY JS, and the EUROPEAN/CANADIAN GLATIRAMER ACETATE STUDY GROUP: European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. Ann. Neurol (2001) 49:290–297.
   PubMed Web of Science ®Google Scholar
• TRAPP BD, RANSOHOFF RM, FISHER E, RUDICK RA: Neurodegeneration in multiple sclerosis: Relationship to neurological disability. Neuroscientist (1999) 5:48–57.
   Web of Science ®Google Scholar
• ••Axonal loss occurs early in MS and is themajor cause of irreversible, progressive disability.
   Google Scholar
• THE IFNB MULTIPLE SCLEROSIS STUDY GROUP, and the UNIVERSITY OF BRITISH COLUMBIA MS/MRI ANALYSIS GROUP: Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology (1995) 45:1277–1285.
   PubMed Web of Science ®Google Scholar
• JOHNSON KP, BROOKS BR, COHEN JA et al.: Extended use of
   Google Scholar
• ••glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology (1998) 50:701–708.
   Google Scholar
• EUROPEAN STUDY GROUP ON INTERFERON BETA-1B IN SECONDARY PROGRESSIVE MS: Placebo-controlled multicentre randomised trial of interferon beta-lb in treatment of secondary progressive multiple sclerosis. Lancet (1998) 352:1491–1497.
   PubMed Web of Science ®Google Scholar
• GOODKIN D, THE NORTH AMERICAN STUDY GROUP ON INTERFERON BETA-lb IN SECONDARY PROGRESSIVE MS: Interferon beta-lb in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial.Neurology (2000) 54:2352 (Abstract).
   Google Scholar
• KILLIAN JM, BRESSLER RB, ARMSTRONG RM: Controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis. Arch. Neurol. (1988) 45:27–30.
   PubMedGoogle Scholar
• GOBBINI MI, SMITH ME,RICHERT ND, FRANK JA, MCFARLAND HE Effect of open label pulse cyclophosphamide therapy on MRI measures of disease activity in five patients with refractory relapsing-remitting multiple sclerosis. Neuroimmunol. (1999) 99:142–149.
   PubMed Web of Science ®Google Scholar
• ••Irnmunosuppression with cyclophosphamide produces a marked reduction in Gd-enhancing lesions with a mean latency of 5 months after starting monthly infusions.
   Google Scholar
• MLLEFIORINI E, GASPERINI C, POZZILLI C et al.: Randomized placebo-controlled trial of mitoxantrone in relapsing- remitting multiple sclerosis: 24-month clinical and MRI outcome.Neurol. (1997) 244:153–159.
   Google Scholar
• •The first randomised, placebo-controlled trial of mitoxantrone assessing effects on relapses, disability progression and MRI outcome in RR MS.
   Google Scholar
• BASTIANELLO S, POZZILLI C, D'ANDREA F et al.: A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year.Can.' Neurol. Sci. (1994) 21:266–270
   Google Scholar
• EDAN G, MILLER D, CLANET M et Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomized multicenter study of active disease using MRI andclinical criteria. I Neurol. Neurosurg Pscyhiatry (1997) 62:112–118.
   PubMed Web of Science ®Google Scholar
• AMATO MP, PRACUCCI G, PONZIANI G, SIRACUSA G, FRATIGLIONI L: Long-term safety of azathioprine therapy in multiple sclerosis. Neurology (1993) 43:831–833.
   PubMedGoogle Scholar
• PALACE J, ROTH WELL P:New treatments and azathioprine in multiple sclerosis. Lancet (1997) 350:261.
   PubMed Web of Science ®Google Scholar
• MARKOVIC-PLESE S, BIELEKOVA B, KADOM N et al: Longitudinal magnetic resonance imaging study on the effect of azathioprine in relapsing-remitting multiple sclerosis patients refractory to the treatment with interferon 3-lb. Neurology (2002) 58\(Suppl. 3):A492.
   Google Scholar
• MILLER DH, KHAN OA,SHEREMATA WA et al: A controlled trial of Natalizumab for relapsing multiple sclerosis. N Engl. Med. (2003) 348:15–23.
   PubMed Web of Science ®Google Scholar
• COLES AJ, WING MG, MOLYNEUX P, PAOLILLO A, DAVIE CM, HALE G: Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis.Ann. Neurol. (1999) 46:296–305.
   PubMed Web of Science ®Google Scholar
• COLES AJ, WING N, SMITH S et al: Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet (1999) 354:1691–1696.
   PubMed Web of Science ®Google Scholar
• GOODKIN DE, PLENCNER S, PALMER-SAXERUD J, TEETZEN M: Cyclophosphamide in chronic progressive multiple sclerosis: maintenance versus nonmaintenance therapy. Arch. Neurol. (1987) 44:823–827.
   PubMedGoogle Scholar
• COOK SD, DEVEREUX C, TROIANO R et al.: Effect of total lymphoid irradiation in chronic progressive multiple sclerosis. Lancet (1986) I:1405–1408.
   Google Scholar
• WEINER HL, COHAN JA: Treatment of multiple sclerosis with cyclophosphamide: critical review of clinical and immunological effects. Mult. Scler: (2002) 8:142–154.
   PubMed Web of Science ®Google Scholar
• ••An extensive review of clinical andimmunological effects of cyclophosphamide in different subtypes and stages of MS.
   Google Scholar
• FIDLER JM, QUINN DEJOY S, GIBBONS JJ Jr: Selective immunomodulation by theantineoplastic agent mitoxantrone. I. Suppression of B lymphocyte function. Immunol. (1986) 137:727–732.
   Google Scholar
• MUSTAFA M, DIENER P, SUN JB, LINK H, OLSSON T: Immunopharmacologic modulation of experimental allergic encephalomyelitis: Low-dose cyclosporin-A treatment causes disease relapse and increased systemic T and B cell mediated myelin-directed autoimmunity. Scand. I Immunol. (1993) 38:499–507.
   PubMedGoogle Scholar
• LEVINE S, GHERSON J: Morphologic effects of mitoxantrone and a related anthracenedione on lymphoid tissues. Int. Immunopharmacol. (1986) 8:999–1007.
   PubMed Web of Science ®Google Scholar
• WANG BS, LUMANGLAS AL, SILVA J, RUSZALA-MALLON VM, DURR FE: Inhibition of the induction ofalloreactivity with mitoxantrone. Immunopharmacol. (1987) 8:967–973.
   Google Scholar
• NEUMANN H, MEDANA IM, BAUER J, LASSMANN H: Cytotoxic T lymphocytes in autoimmune and degenerative CNS diseases. Trends Neurosci. (2002) 25:313–319.
   PubMed Web of Science ®Google Scholar
• GIULIANI F, GOODYER CG, ANTEL JP, YONG VW: Vulnerability of human neurons to T cell-mediated cytotoxicity. Immunol. (2003) 171:368–379.
   Google Scholar
• FIDLER JM, DEJOY SQ, SMITH FR 3rd, GIBBONS JJ Jr: Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone-treated mice. 1 Immunol. (1986) 136:2747–2754.
   Google Scholar
• WATSON CM, DAVISON AN, BAKER D, O'NEILL JK, TURK JL: Suppression of demyelination by mitoxantrone. Int. .1. Immunopharmacol. (1991) 13:923–930.
   Google Scholar
• EHNINGER G, PROKSCH B, HEINZEL G, WOODWARD DL: Clinical pharmacology of mitoxantrone. Cancer Treat. Rep. (1986) 70:1373–1378.
   PubMedGoogle Scholar
• VAN BELLE SJP, DE PLANQUE MM, SMITH IE et al: Pharmacolkinetics of mitoxantrone in humans following single-agent infusion or intra-arterial injection therapy or combined-agent infusion therapy. Cancer Chemother: Pharmacol. (1986) 18:27–32.
   PubMedGoogle Scholar
• ROBOZ J, PACIUCCI PA, SILIDES D, GREAVES J, HOLLAND JF: Detection and quantification of mitoxantrone in human organs. A case report. Cancer Chemother: Pharmacol. (1984) 13:67–68.
   PubMed Web of Science ®Google Scholar
• STEWART DJ, GREEN RM, MIKHAEL NZ, MONTPETIT V,THIBAULT M, MAROUN JA: Human autopsy tissue concentrations of mitoxantrone. Cancer Treat Rep (1986) 70:1255–1261.
   PubMedGoogle Scholar
• LU K, SAVARAJ N, LOO TL: Pharmacological disposition of 1,4-dihydroxy 5 8 bis [[2[(2-hydroxyethal) amino] ethyl] amino] -9,10-anthracenedione dihydrochloride in the dog. Cancer Chemother. Pharmacol (1984) 13:63–66.
   PubMed Web of Science ®Google Scholar
• ALBERTS DS, PENG YM, BOWDEN GT, DALTON WS, MACKEL C: Pharmacology of mitoxantrone: mode of action and pharmacokinetics. Invest. New Drugs (1985) 3:101–107.
   PubMed Web of Science ®Google Scholar
• GREIDANUS J, DE VRIES EG, MULDER NH et al.: A Phase I pharmacokinetic study of 21-day continuous infusion mitoxantrone.Clin. Oncol (1989) 7:790–797.
   Google Scholar
• RIDGE SC, SLOBODA AE,MCREYNOLDS RA et al.: Suppression of experimental allergic encephalomyelitis by mitoxantrone. Clin. Immunol Immunopathol (1985) 35:35–42.
   PubMedGoogle Scholar
• LEVINE S, SALTZMAN A: Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by mitoxantrone.Neuroimmunol (1986) 13:175–181.
   PubMed Web of Science ®Google Scholar
• LUBLIN FD, LA VASA M, VITI C, KNOBLER RL: Suppression of acute and relapsing experimental allergic encephalomyelitis with mitoxantrone. Clin. Immunol Immunopathol (1987) 45:122–128.
   PubMedGoogle Scholar
• GONSETTE RE, DEMONTY L: Mitoxantrone: a new immunosuppressive agent in multiple sclerosis. In: Recent advances in multiple sclerosis therapy Gonsette RE Delmotte P (Ed.), Elsevier Science Publishers BV (1989):11–164.
   Google Scholar
• GONSETTE RE, DEMONTY L: Immunosuppression with mitoxantrone in multiple sclerosis: a pilot study for 2 years in 22 patients. Neurology(1990)40\(Suppl. 1):261.
   Google Scholar
• KAPPOS L, GOLD R, KUNSTLER E, ROHRBACH E, HEUN R, STADT D: Mitoxantrone (Mx) in the treatment of rapidly progressive MS: A pilot study with serial gadolinum (Gd)-enhanced MRI. Neurology(1990) 40\(Suppl. 1):261.
   Google Scholar
• •The first demonstration of a positive effect in the treatment on brain lesion activity with MRI in MS patients.
   Google Scholar
• NOSEWORTHY JH, LEE D,PENMAN M et al: A Phase II evaluation of mitoxantrone HC1 in the treatment of progressive multiple sclerosis. Neurology (1991) 41 (Suppl. 1):146.
   Google Scholar
• RUTTINGER H, MARTIN J: Demonstration of MS-plaques activated during immunosuppression with mitoxantrone by gadolinium-enhanced MRI. Akt Neurol .(1992) 19:13–15.
   Google Scholar
• MAUCH E, KORNHUBER HH: Die immunsuppressive Therapie der multiplen Sklerose mit Mitoxantron. Fortschr: Neurol Psych. (1993) 61:410–417.
   PubMedGoogle Scholar
• KRAPF H, MAUCH E, FETZER U, LAUFEN H: Serial gadolinium-enhanced magnetic resonance imaging in patients with multiple sclerosis treated with mitoxantrone. Neuroradiology (1995) 37:113–120.
   PubMed Web of Science ®Google Scholar
• NOSEWORTHY JH, HOPKINS MB, VANDERVOORT MK et al: An open-trial evaluation of mitoxantrone in the treatment of progressive MS. Neurology (1993) 43:1401–1406.
   PubMed Web of Science ®Google Scholar
• GONSETTE RE: m -itoxantrone immunotherapy in multiple sclerosis. Malt. Scler. (1996) 1:329–332.
   PubMedGoogle Scholar
• ••A retrospective clinical overview stressingthe long-term toxicity of mitoxantrone and the maximum cumulative dose in patients with MS.
   Google Scholar
• HARTUNG HP, GONSETTE R, KONIG N et al.: Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double blind, randomised, multicentre trial. Lancet (2002) 360:2018–2025.
   PubMed Web of Science ®Google Scholar
• ••A large-scale, placebo-controlled trial withmitoxantrone in progressive MS assessing clinical and MRI efficacy.
   Google Scholar
• JEFFERY DR, LEFKOWITZ DS, CRITTENDEN JP: Treatment of Marburg variant multiple sclerosis with mitoxantrone. .1. Neuroimaging (2004) 14:58–62.
   PubMed Web of Science ®Google Scholar
• LA MANTIA L, EOLI M, SALMAGGI A, TORRI V, MILANESE C: Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study. Ital. Neurol Sci. (1998) 19:32–36.
   PubMedGoogle Scholar
• SHENKENBERG TD, VON HOFF DD: Possible mitoxantrone-induced amenorrhea. Cancer Treat. Rep. (1986) 70:659–661.
   PubMedGoogle Scholar
• DE CASTRO S, CARTONI D, MILLEFIORINI E et al.: Noninvasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. Clin. Pharmacol (1995) 35:627–632.
   Google Scholar
• GHALIE RG, EDAN G, LAURENT M et al.: Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology (2002) 59:909–913.
   PubMed Web of Science ®Google Scholar
• ACEVEDO AR, NAVA C, ARRIADA V, VIOLANTE A, CORONA T: Cardiovascular dysfunction in multiple sclerosis. Acta Neurol Scand. (2000) 101:85–88.
   PubMed Web of Science ®Google Scholar
• OLINDO S, GUILLON B, HELIAS J, PHILLIBERT B, MAGNE C, FEVE JR: Decrease in heart ventricular ejection fraction during multiple sclerosis. Eurj Neurol (2002) 9:287–291.
   Google Scholar
• STROTMANN JM, SPINDLER M, WEILBACH FX, GOLD R, ERTL G, VOELKER W: Myocardial function in patients with multiple sclerosis treated with low-dose mitoxantrone. Amer J. Cardiol (2002) 89:1222–1225.
   PubMed Web of Science ®Google Scholar
• SPINDLER M, WEILBACH F, BEER M et al.: Non-invasive functional and biochemical assessment of mitoxantrone cardiotoxicity in patients with multiple sclerosis. Cardiovasc. Pharmacol (2003) 42:680–687.
   PubMed Web of Science ®Google Scholar
• AVASARALA JR, CROSS AH, CLIFFORD DB, SINGER BA, SIEGEL BA, ABBEY E: Rapid onset mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult. &ler: (2003) 9:59–62.
   Google Scholar
• GBADAMOSI J, MUNCHAU A, WEILLER C, SCHAFER H: Severe heart failure in a young multiple sclerosis patient. Neurol (2003) 250:241–242.
   Google Scholar
• JENSEN BV, SKOVSGAARD T, NIELSEN SL: Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann. Oncol (2002) 13:699–709.
   PubMed Web of Science ®Google Scholar
• AUNER HW, TINCHON C, LINKESCH W et al.: Prolonged monitoring of troponin T for the detection of anthracycline cardiotoxicity in adults with hematological malignancies. Ann. Hematol (2003) 82:218–222.
   PubMed Web of Science ®Google Scholar
• WILSTERMANN AM, OSHEROFF N: Stabilization of eukaryotic topoisomerase II- DNA cleavage complexes. Can: Top. Med. Chem. (2003) 3:321–338.
   PubMedGoogle Scholar
• ANDOH T: Mechanism of occurrence of secondary tumors by antitumor drugs. Gan To Kagaku Ryoho (1999) 26:1988–1998.
   PubMedGoogle Scholar
• CHAPLAIN G, MILAN C, SGRO C, CARLI PM, BONITHON-KOPP C: Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study. j. Clin. Oncol (2000) 18:2836–2842.
   PubMed Web of Science ®Google Scholar
• BEAUMONT M, SANZ M, CARLI PM: Therapy related acute promyelocytic leukemia. Clin. Oncol (2003) 21:2123–2137.
   Google Scholar
• DASSONNEVILLE L, BAILLY C: Chromosome translocations and leukemias induced by inhibitors of topoisomerase II anticarcinogenic drugs. Bull. Cancer (1998) 85:254–261.
   PubMedGoogle Scholar
• VICARI AM, CICERI F, FOLLI F: Acute promyelocytic leukemia following mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia (1998) 12:441–442.
   PubMed Web of Science ®Google Scholar
• BRASSAT D, RECHER C, WAUBANT E et al.: Therapy-related acute myeloblastic leukemia after mitoxantrone treatment in a patient with MS. Neurology (2002) 59:954–955.
   PubMed Web of Science ®Google Scholar
• RADU TD, MARC D, HEVE V: Acute myeloid leukaemia (AML) induced by mitoxantrone. Mult. &ler: (2002) 8\(Suppl. 1):5127.
   Google Scholar
• HEESEN C, BRUEGMANN M, GBDAMOSI J, KOCH E, MONCH A, BUHMANN C: Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with mitoxantrone. Mult. &ler: (2003) 9:213–214.
   Google Scholar
• CATTANEO C, ALMICI C, BORLENGHI E, MOTTA M, ROSSI G: A case of acute promyelocytic leukaemia following mitoxantrone treatment of multiple sclerosis. Leukemia (2003) 17:985–986.
   PubMedGoogle Scholar
• MOGENET I, SIMIAND-ERDOCIAIN E, CANONGEJM, PRISJ: Acute myelogenous leukemia following mitoxantrone treatment for multiple sclerosis. Ann. Pharmacother. (2003) 37:747–748.
   PubMed Web of Science ®Google Scholar
• DELISSE B, DE SEZE J, MACKOWIAK A et al.: Therapy-related acute myeloblastic leukaemia after mitoxantrone treatment in a patient with multiple sclerosis. Mult. Scler. (2003) 9\(Suppl. 1):5121.
   Google Scholar
• LINASSIER C, BARIN C, CALAIS C et al.: Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy. Ann. Oncol (2000) 11:1289–1294.
   PubMed Web of Science ®Google Scholar
• GHALIE RG, MAUCH E, EDAN G et al: A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult. &ler: (2002) 8:441–445.
   Google Scholar
• ANDERSSON BS, EKSBORG S, VIDAL RF, SUNDBERG M, CARLBERG M: Anthraquinone-induced cell injury: acute toxicity of carminomycin, epirubicin, idarubicin and mitoxantrone in isolated cardiomyocytes. Toxicology (1999) 135:11–20.
   PubMedGoogle Scholar
• KAHLES H, BASTIAN HJ, SCHIFFMANN 0, GECK M, HELMKE FR, GOLZ N: Mitoxantrone-induced acute left heart failure after intrapleural administration. Herz (1997) 22:217–220.
   PubMedGoogle Scholar
• FRISHMAN WH, SUNG HM, YEE HC et al.: Cardiovascular toxicity with cancer chemotherapy. Carr. Pro& Cancer (1997) 21:301–360.
   PubMedGoogle Scholar
• PAI VB, NAHATA MC: Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Sal: (2000) 22:263–302.
   PubMed Web of Science ®Google Scholar
• HORTOBAGYI GN, FRUYE D, BUZDAR AU et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer (1989) 63:37–45.
   PubMed Web of Science ®Google Scholar
• GOKHALE PC, PEI J, ZHANG C, AHMAD I, RAHMAN A, KASID U: Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anti-Cancer Res. (2001) 21:3313–3321.
   PubMed Web of Science ®Google Scholar
• VENDITTI P, BALESTRIERI M, DE LEO T, DI MEO S: Free radical involvement in doxorubicin-induced electrophysiological alterations in rat papillary muscle fibres. Cardiovasc. Res. (1998) 38:695–702.
   PubMed Web of Science ®Google Scholar
• WEILBACH FX, CHAN A, TOYKA KV, GOLD R: The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Gin. Exp. Immunol (2004) 135:49–55.
   PubMedGoogle Scholar
• HERMAN EH, FERRANS VJ, MYERS CE, VAN VLEET JF: Comparison of the effectiveness of (+/-)-1,2-bis(3,5-dioxopiperazinyl-1-y1)propane (ICRF-187) and N-acetylcysteine in preventing chronic doxorubicin cardiotoxicity in beagles. Cancer Res. (1985) 45:276–281.
   PubMed Web of Science ®Google Scholar
• SPEYER JL, GREEN MD, ZELENIUCH-JACQUOTTE A et al: ICRF-187 permits longer treatment with doxorubicin in women with breast cancer. I Clin. Oncol (1992) 10:117–127.
   PubMed Web of Science ®Google Scholar
• SEYMOUR L, BRAMWELL V, MORAN LA: Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. The Provincial Systemic Treatment Disease Site Group. Cancer Prey Control (1999) 3:145–159.
   PubMedGoogle Scholar
• ALDERTON PM, GROSS J, GREEN MD: Comparative study of doxorubicin, mitoxantrone, and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res. (1992) 52:194–201.
   PubMed Web of Science ®Google Scholar
• KOUTINOS G, STATHOPOULOS GP, DONTAS I et al: The effect of doxorubicin and its analogue mitoxantrone on cardiac muscle and on serum lipids: an experimental study. Anti-Cancer Res. (2002) 22:815–820.
   PubMed Web of Science ®Google Scholar
• HERMAN EH, ZHANG J, HASINOFF BB, CLARK JR Jr, FERRANS VJ: Comparison of the structural changes induced by doxorubicin and mitoxantrone in the heart, kidney and intestine and characterization of the Fe(III)-mitoxantrone complex. Ma Cell. Cardiol (1997) 29:2415–2430.
   PubMed Web of Science ®Google Scholar
• KITA M, GOODKIN DE, OLSON M, CAMPBELL J: A pilot study of mitoxantrone plus dexrazoxane versus mitoxantrone in patients with relapsing remitting, secondary progressive and progressive relapsing MS. Neurology (2003) 60\(Suppl. 1):A149.
   Google Scholar
• FADILLIOGLU E, ERDOGAN H, SOGUT S, KUKU I: Protective effects of erdosteine against doxorubicin-induced cardiomyopathy in rats. Appl. Toxicol (2003) 23:71–74.
   Google Scholar
• KRAPCHO AP, LANDI JJ Jr, HACKER MP, McCORMACK JJ. Synthesis of antineoplastic evaluations of 5,8-bis [(aminoalkyl) amino]- 1–
   Google Scholar
• •• azaanthracene-9,10-diones. J. Med. Chem. (1985) 28:1124–1126.
   PubMedGoogle Scholar
• KRAPCHO AP, MARESCH MJ, HACKER MP et al.: Anthracene-9,10-diones and Aza Bioisosteres as antitumor agents. Carr Med Chem (1995) 2:803–824.
   Web of Science ®Google Scholar
• BEGGIOLIN G, CRIPPA L, MENTA E et al.: BBR2778, an aza-anthracenedione endowed with preclinical anticancer activity and lack of delayed cardiotoxicity. Tumori (2001) 87:407–416.
   PubMed Web of Science ®Google Scholar
• CAVALLETTI E, CRIPPA L, BELLINI 0, MENTA E, CAVAGNOLI R, DELBO D: 9-Aza-anthrapyrazoles devoid of cardiotoxic effects. Proc. Am. Assoc. Cancer Res. (1996) 37:abstr 2662.
   Google Scholar
• DUBOIS B, GONSETTE R, DILLEN C, BILLIAU A: Efficacy of a novel non-cardiotoxic aza-anthracenedione (BBR2778) in acute EAE. Malt. Scler. (2001) 7\(Suppl. 1):S20(P–010).
   Google Scholar
• CAVALETTI G, FRIGO M, ROTA S et al: BBR2778, a new non-cardiotoxic drug structurally related to mitoxantrone, reduces the severity of rat acute and chronic experimental allergic encephalomyelitis. Malt. Scler. (2002) 8\(Suppl. 1):568.
   Google Scholar
• BBR2778. Investigator Drug Brochure, July (2002) edition 6. 134. DAWSON LK, JODRELL DI, BOWMAN A et al.: A clinical Phase I and pharmacokinetic study of BBR2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur. Cancer (2000) 36:2353–2359.
   Google Scholar
• FAIVRE S, RAYMOND E, BOIGE V et al.: A Phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR2778 in patients with advanced solid malignancies.Clin. Cancer Res. (2001) 7:43–50.
   Google Scholar
• BORCHMANN P, SCHNELL R, KNIPPERTZ R: Phase I study of BBR2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol (2001) 12:661–667.
   PubMed Web of Science ®Google Scholar
• LEPAGE E, LERAY, DEBOUVERIE M et al.: Induction treatment with mitoxantrone in worsening relapsing remitting multiple sclerosis: a 'rescue therapy' for sub-optimal responders to interferon beta? A pilot study. Neurology (2003) 60\(Suppl. 1):A149.
   Google Scholar
• PERINI P, GALLO P: Cyclophosphamide is effective in stabilizing rapidly deteriorating secondary progressive multiple sclerosis. Neurol (2003) 250:834–838.
   Google Scholar
• GOTTESMAN M, FRIEDMAN-UREVICH S: Results from the IDEAS study: high-dose interferon beta-lb in MS treatment. Mult. Scler. (2003) 9\(Suppl. 1):595.
   Google Scholar
• HURWITZ B, ARNASON BG, GILEY GK et al.: Betaseron®/Betaferon® efficacy yielding outcomes of a new dose (BEYOND) - safety and tolerability of 500 mcg versus 250 mcg of interferon beta-lb. Malt. Scler. (2003) 9\(Suppl. 1):540.
   Google Scholar
• GOGGIN T, VIGNA E, NEUTEBOOM B, TRINCHARD-LUGAN I, KLETZL H: Non-covalent complex of interferon beta-la and recombinant human Type I interferon receptor subunit 2 a: preclinical and Phase I results. Malt. Scler: (2003) 9\(Suppl. 1):5138.
   Google Scholar
• MACHKHAS H, HARATI Y: Side effects of immunosuppressant therapies used in neurology. Neurol Clin. (1998) 16:171–188.
   PubMedGoogle Scholar
• CONNELL WR, KAMM MA, RITCHIE JK, LENNARD-JONES JE: Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut (1994) 34:1081–1085.
   Google Scholar
• CONNELL WR, KAMM MA, DICKSON M, BALKWILL AM, RITCHIE JK, LENNARD-JONES JE: Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet (1994) 343:1249–1252.
   PubMed Web of Science ®Google Scholar
• CONFAVREUX C, SADDIER P, GRIMAUD J, MOREAU T, ADELEINE P, AIMARD G: Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology (1996) 46:1607–1612.
   PubMed Web of Science ®Google Scholar
• DE RIDDER D, VAN POPPEL H, DEMONTY L et al.: Bladder cancer in patients with multiple sclerosis treated with cyclophosphamide. Urol. (1998) 159:1881–1884.
   Google Scholar
• GONSETTE RE: m mitoxantrone in progressive multiple sclerosis: when and how to treat?' Neurol Sci. (2003) 206:203–208.
   Google Scholar
• ••Revised guidance concerning indicationsand treatment regimens with mitoxantrone in MS.
   Google Scholar
• STARZL TE, MURASE N, ABU-ELMAGD K et al.: Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 361:1502–1510.
   PubMed Web of Science ®Google Scholar
• TRAVIS LB, CURTIS RE, GLIMELIUS B et al.: Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. I Natl. Cancer Inst. (1995) 87:524–530.
   PubMed Web of Science ®Google Scholar
• SISSI C, MORO S, RICHTER S: DNA-interactive anticancer Aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. Ma Pharmacol (2001) 59:96–103.
   PubMed Web of Science ®Google Scholar
• PARKIN D, JACOBY A, MCNAMEE P, MILLER P, THOMAS S, BATES D: Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life. Neurol Neursurg. Psych. (2000) 68:144–149.
   PubMed Web of Science ®Google Scholar
• BROWN MG, MURRAY TJ, SKETRIS IS et al.: Cost-effectiveness of interferon beta-lb in slowing multiple sclerosis disability progression. First estimates. Int. Technol Assess. Health Care (2000) 16:751–767.
   PubMed Web of Science ®Google Scholar
• COYLE PK, VOLLMER T, LEPEN C et al.: Long-term cost-effectiveness of interferon beta-la (Rebif 44 pg tiw) in the treatment of relapsing-remitting multiple sclerosis: an econometric model. Neurol (2002) 249\(Suppl. 1):201–202.
   Google Scholar
• FORBES RB, LEES A, WAUGH N, SWINGLER RJ: Population based cost utility study of interferon beta-lb in secondary progressive multiple sclerosis. Br. Med. J. (2000) 319:1529–1533.
   Google Scholar
• KOBELT G, JONSSON L, HENRIKSSON F, FREDRIKSON S, JONSSON B: Cost-utility analysis of interferon beta-lb in secondary progressive multiple sclerosis. Int. Technol Assess. Health Care (2000) 16:768–780.
   PubMed Web of Science ®Google Scholar
• NUIJTEN MJ, HUTTON J: Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis. Value Health (2002) 5:44–54.
   PubMed Web of Science ®Google Scholar
• CHILCOTT J, MCCABE C, TAPPENDEN P et al.: Modelling the cost effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. Commentary: evaluating disease modifying treatments in multiple sclerosis. Br. Med. (2003) 326: 522.
   Google Scholar
• TOUCHETTE DR, DURGIN TL, WANKE LA, GOODKIN DE: A cost-utility analysis of mitoxantrone hydrochloride and interferon beta-lb in the
   Google Scholar
• •• treatment of patients with secondary progressive or progressive relapsing multiple sclerosis. Clin. Thar. (2003) 25:611–634.
   Google Scholar
• ••A cost-utility analysis comparingmitoxantrone, IFN-131, and supportive care.
   Google Scholar
• KOBELT G, JONSSON L, MILTENBURGER C, JONSSON B: Cost-utility analysis of interferon beta-1B in secondary progressive multiple sclerosis using natural history disease data. Int. I Technol. Assays. Health Care (2002) 18:127–138.
   PubMed Web of Science ®Google Scholar
• LAUPACIS A, FEENY D, DETSKY AS, TUGWELL PX: How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ(1992) 146:473–481.
   PubMed Web of Science ®Google Scholar
• FLACHENECKER P, RIECKMANN P: Early intervention in multiple sclerosis: better outcomes for patients and society? Drugs (2003) 63:1525–1533.
   PubMedGoogle Scholar